AACR spotlighted dual-payload antibody-drug conjugates as a next-generation modality as the field pushes into clinical translation. The Biocentury product development coverage cited more than 40 abstracts focused on countering payload resistance and tumor heterogeneity—two recurring problems in ADC performance. Across designs, teams are pursuing ADC architectures intended to improve how drug payloads behave inside diverse tumor microenvironments and to reduce the likelihood that resistance emerges through single-agent pathways. For biotech teams, the AACR cluster suggests demand for combination-like effects without abandoning the ADC format, increasing the competitive pressure to generate comparative preclinical efficacy and resistance models that can support future trial designs.